Compare · AKUS vs VOR
AKUS vs VOR
Side-by-side comparison of Akouos Inc. (AKUS) and Vor Biopharma Inc. (VOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- AKUS operates in Consumer Discretionary, while VOR operates in Health Care - the two are in different parts of the market.
- VOR is the larger of the two at $728.3M, about 3.7x AKUS ($197.0M).
- VOR has hit the wire 6 times in the past 4 weeks while AKUS has been quiet.
- VOR has more recent analyst coverage (16 ratings vs 1 for AKUS).
- Company
- Akouos Inc.
- Vor Biopharma Inc.
- Price
- $13.29+1.10%
- $14.04+4.31%
- Market cap
- $197.0M
- $728.3M
- 1M return
- -
- -8.04%
- 1Y return
- -
- +212.23%
- Industry
- Specialty Chemicals
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 1
- 16
Akouos Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Vor Biopharma Inc.
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest AKUS
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form 15-12G filed by Akouos Inc.
- SEC Form EFFECT filed by Akouos Inc.
- SEC Form 4 filed by Walker Paul Edward (tax withholding)
- SEC Form 4 filed by Sonsini Peter W. (tax withholding)
- SEC Form 4 filed by Sandell Scott D to satisfy withholding tax
- SEC Form 4 filed by Mathers Edward T (tax withholding)
Latest VOR
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
- SEC Form 10-Q filed by Vor Biopharma Inc.
- Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form EFFECT filed by Vor Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)